COSENTYX mechanism of action

  • Selectively binds to IL-17A, inhibiting interaction with IL-17 receptor and subsequent release of proinflammatory cytokines and chemokines1
  • Elevated levels of IL-17A have been found in the blood of patients with AS1

IL=interleukin.

References: 1. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016. 2. Baeten D. Etiology, pathogenesis, and pathophysiology of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 6th ed. Philadelphia, PA: Elsevier; 2015:102-113.